The Isabella and Marcus Foundation is contributing funding to a new clinical trial for DIPG and Diffuse Midline Gliomas in children and young adults in Australia and New Zealand. This trial will evaluate a promising new drug combination of ONC201 and paxalisib. Treatment will be available at initial diagnosis, post-radiation or at time of progression. The trial, due to commence in the second half of 2022, will be conducted by the Australian and New Zealand Childrens Haemotology/Oncology Group and is co-sponsored by the International Pacific Pediatric Neuro-Oncology Consortium. More information as it becomes available can be found at: https://tinyurl.com/4vked7u8
The Isabella and Marcus Foundation, in partnership with Cure Brain Cancer Foundation funded the Australasian participation in the ‘International BIOMEDE (Biological Medicine for Diffuse Intrinsic Pontine Glioma Eradication) study’ from 2018-2020. This clinical trial was available to treat 24 children in Australia and New Zealand newly diagnosed with DIPG as part of a worldwide cohort of 250 children. The study evaluated the efficacy of 3 drugs in combination with radiotherapy. The choice of drug was determined by the mutation(s) found in a biopsy of each child’s tumour, with each drug specifically acting on one type of mutation commonly found in DIPG. The study was conducted by the Australian and New Zealand Children’s Haematology/Oncology Group and was led by Dr Geoff McCowage at the Children’s Hospital at Westmead, Sydney.
The Isabella and Marcus Foundation is a member of the International DIPG Collaborative, one of 24 like-minded charities around the world that collaborate to fund DIPG projects. The annual contribution from the Isabella and Marcus Foundation supports Australian researchers and the 2019 International DIPG Symposium in Sydney.
The Isabella and Marcus Foundation provides seed funding for DIPG projects, providing researchers with an opportunity to start research that wouldn't otherwise be funded. The data generated can then be used to apply for large government grants that will accelerate research to develop treatments for DIPG and other Diffuse Midline Glioma's.
Dr Misty Jenkins
Walter and Eliza Hall Institute of Medical Research
Immunotherapy is an exciting recent development for the treatment of cancer, with proven efficacy for a number of cancers. Dr Misty Jenkins and her team of researchers from WEHI (fomerly the Walter and Eliza Hall Institute of Medical Research) is developing CAR-T cell therapy , which supercharges the child’s own immune system so that it can effectively destroy DIPG cells. The treatment will involve taking a sample of blood from the child, purifying the immune cells, which are re-engineered in the laboratory to recognise and kill DIPG cells and then infused in large numbers back into the child.
Dr Lee Wong
Dr Wong specialises in telomeres, which are complexes found at the ends of chromosomes that are absolutely essential for maintaining chromosome stability. Each time a cell divides, telomeres become shorter and when the cells have gone through many divisions the telomeres become so short that the cells die. This is a protective mechanism against cancer because mutations can accumulate after many cell divisions. However, in some cancer cells, the telomeres do not shorten because an enzyme called telomerase is expressed at higher than normal levels or because a series of molecular events called "Alternative Lengthening of Telomeres (ALT) is turned on. This ALT pathway is common in brain tumours. Most children with DIPG express a mutation that is associated with the ALT pathway. This study investigated the link between this mutation in a Histone 3.3 gene and switching on the ALT pathway.
Jeff is preparing pre-clinical models of DIPG that recapitulate the disease that occurs in children. In its first iteration the model will incorporate the 2 most common mutations observed in children, which are thought to drive the development of the tumour. These mutations, H3.3 K27M and p53 have been genetically introduced into the DNA of the model and sit alongside the normal genes, which are functional until they are replaced by the mutated genes by introducting tamoxifen into the drinking water. A reporter gene, also under the control of tamoxifen, has also been introduced to highlight the area(s) of the brain that express the mutations.
All of the genetic modifications have been introduced. The model is now being evaluated to determine if the mutations trigger the development of DIPG. The model will then be provided to a central repository as a resource for all DIPG researchers worldwide to help fast track treatments.
This work is co-funded by Brainchild Foundation.
Dr. Jason Cain
The Hudson Institute
Over the last 10 years our understanding of the genetic and molecular landscape of DIPG has greatly improved. As a result, great effort has gone into trying to identify potential new therapies using DIPG cell culture models but despite promising results, these treatments have had limited effects on DIPG growth in living models and/or in patient clinical trials. The failure to successfully apply findings from DIPG cells grown in plastic culture dishes in the laboratory could be explained by the likelihood that these cells function differently in culture than in the brain, and therefore respond differently to treatment. Dr Jason Cain and his PhD student, Shaye Game (Elliot Gautsch Scholar) are undertaking novel genetic screens to identify pathways required for DIPG survival in clinically relevant DIPG models that can be targeted by existing drugs that are currently used for other diseases.
Brain Cancer Biobank
Brain cancer researchers need ready access to samples for study. Tissue specimens from children are rare and finding appropriate samples in institutions around the country is difficult. Procedures to access samples also differ across the various institutions. Linking the various biobanks across Australia into a single network and portal will enable research by providing ready access to specimens.
‘Brain Cancer Biobanking Australia’ is an initiative of Robyn Leonard (Founder) whose daughter Lucie died from brain cancer. The Isabella and Marcus Fund is supported this initiative until from 2016 to 2019.
The charity regularly sponsors scientific meetings that bring DIPG/DMG researchers together to share their knowledge. Scientific exchange provides an impetus for scientific progress and encourages collaborations between laboratories. In 2019, the Isabella and Marcus Foundation sponsored (i) the International DIPG Symposium in Sydney (Aug 2nd - 3rd) and the Cell Signalling and its Therapeutic Implications: Focus on Cancer (May 13th - 15th). Each year, it support the Childhood Cancer Research Symposium at the Hudson Insitute of Medical Research.
Our scholarship program addressed the historical shortfall in scientists that study DIPG/DMG. The charity is providing PhD scholarships to graduate students, some of whom will become the next generation of paediatric brain cancer scientists. These scholarships are named in memory of children who lived with DIPG. 9 scholarships are currently funded with more planned for 2023. These scholarships are funded by the charity’s long-term association with Upstream Foundation.
The Isabella and Marcus Foundation is a member of a the 'Low Survival Cancers Alliance' committee, chaired by the Cancer Council Victoria. The committee advocates for increased funding for cancers with 5 year survival rates below 50%. In Victoria, these cancers represent 20% of all cancer diagnoses but encompass 50% of cancer deaths.
The committee was established in March 2016. Advocacy resulted in $1.5 million in funding by the Victorian government, which was backed by a further $1 million dollars from the Cancer Council of Victoria.
In June 2017 the Isabella and Marcus Foundation presented to the Federal Senate Select Committtee investigating Funding for Research into Cancers with Low Survival Rates.
Professor Peter Rogers University of Melbourne
Conventional radiotherapy is a routine palliative treatment for children with DIPG and provides a temporary reduction in symptoms. Children typically receive 30 treatments over 6 weeks. But conventional radiotherapy is not curative and no other treatments are available. Microbeam radiation therapy is a novel, experimental radiotherapy in which X-rays are generated from a synchrotron. This form of radiotherapy delivers higher doses of radiation in a SINGLE treatment and the beams are shaped to reduce damage to the healthy tissues of the brain. It is being investigated as a curative treatment for DIPG and has shown early promise.
This study demonstrated that doses 20 times higher than conventional radiotherapy could be delivered safely. This exciting finding paves the way for additional studies in preparation for future clinical trials.
This pilot project comprised a multidisciplinary group including physicists, radiotherapists and cancer biologists. A follow up study will occur to examine the efficacy of this treatment for DIPG relative to conventional radiotherapy.
Low Survival Cancers Alliance